Drug Detail:Vorapaxar (Vorapaxar [ vor-a-pax-ar ])
Drug Class: Protease-activated receptor-1 antagonists
Usual Adult Dose for Thromboembolic Disorder
2.08 mg orally once a day, with or without food
Comments: Use with aspirin and/or clopidogrel
Uses: For reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD)
Usual Adult Dose for Peripheral Arterial Disease
2.08 mg orally once a day, with or without food
Comments: Use with aspirin and/or clopidogrel
Uses: For reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD)
Renal Dose Adjustments
No adjustment recommended.
Liver Dose Adjustments
Mild and moderate hepatic impairment: No adjustment recommended.
Severe hepatic impairment: Not recommended.
Precautions
US BOXED WARNING:
- BLEEDING RISK: Do not use vorapaxar in patients with a history of stroke, transient ischemic attack, intracranial hemorrhage (ICH), or active pathological bleeding. Antiplatelet agents, including this drug, increase the risk of bleeding, including ICH and fatal bleeding.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Administer with or without food.
- Use this drug with aspirin and/or clopidogrel according to indications or standard of care.
Patient advice:
- This drug should not be discontinued without physician advice.
- Report any unanticipated, prolonged or excessive bleeding, or blood in stool or urine.
- Inform physicians and dentists that you are taking this drug before any surgery or dental procedure.
- Advise patients that breastfeeding is not recommended during treatment with this drug.
